Equity-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2022

Share-Based Payment Arrangement [Abstract]

Schedule of management contingent share plan

	Management Contingent Share Plan			Grant Date Fair Value
Beginning of year		-		$	-
Granted		9,200,000		$	7.81
Forfeited		(3,683,000	)	$	7.81
End of year		5,517,000		$	7.81
Vested		1,169,000		$	7.81

Schedule of stock option activity

	Stock Option Awards			Weighted- Average Exercise Price		Average Remaining Life (Years)		Aggregate Intrinsic Value
Beginning of year		2,828,307		$	6.51
Granted		204,181		$	15.75
Exercised		(14,796	)	$	6.51
Forfeited		(252,593	)	$	8.36
End of year		2,765,099		$	7.02		2.77	$	-
Exercisable at end of year		2,480,991		$	6.70		2.67	$	-

Schedule of fair value of stock option is a Black-Scholes

	2022			2021
Expected term (years)		3.2			2.3
Expected volatility		70.0	%		94.3	%
Risk-free interest rate		1.38	%		0.24	%
Expected dividend yield		0.0	%		0.0	%
Per-share weighted average grant date fair value	$	15.75		$	0.59

Schedule of equity-based compensation expense

	2022		2021
Research and development1	$	110	$	(19	)
Selling, general and administrative		834		150
Total equity based compensation expense	$	944	$	131

1) Had the Company recorded the Management Contingent Share Plan within research and development and selling, general and administrative expense, then research and development would have been higher by $201 with the remaining expense recognized within selling, general and administrative expense.